Nanoncolytics

Image

Nanoparticle packaging of therapeutics for delivery within the bloodstream, better accumulation within tumours and targeted release.  This enables dose reduction and lower risk of side effects. NANOncolytics overcomes current limitations of nanoformulation using their own bespoke microfluidics device to rapidly and reproducibly manufacture packaged therapies for client use or accurate assessment of their benefits in bespoke cancer models in-house.

Founder:

Faith Howard

Natalie Winder

Problem

The use of nanoparticles (NP) has transformed cancer treatment (e.g. Doxil and Myocet). Despite this, NP development is limited to exploratory in vivo and in vitro studies, and the number of approved NP based drugs has not progressed. To reach patients in a timely manner, NP based drug production requires standardisation to address their large scale manufacture, reproducibility, shelf life, intellectual property (IP), and cost-effectiveness in comparison to current therapies.

Solution

Using a bespoke microfluidic device, we can produce a range of controllable, reproducible and scalable nanoparticles including exosomes, nanohydrogels and lipid, magnetic and silk fibroin NPs. This platform of nanomedicine solutions will revolutionise precision cancer treatment. 

Market 

1)    Medical research groups who require DDSs for their new therapeutics. 2)    Medical research groups who currently employ microfluidics to make DDSs. 3)    Clinicians because of their high translational relevance. 4)    Nanomaterials groups who use microfluidics to make nanomaterials for other applications including energy, catalysis, food, cosmetics, and environment. 5)    Engineers working in the strategic field of manufacturing industry, an area of signposted high priority for UK research.

Contact

Faith Nutter Howard

Image